For the high KLK1 expression subgroup, we found significantly enriched pathways related to asthma, allograft rejection, systemic lupus erythematosus, type I diabetes, and the impact on intestinal immune networks for IgA production, among others (Figure 7A). This evidence concerns the gene KLK1 and systemic lupus erythematosus.